A Phase Ib/II Study of IV Nivolumab and Intrapleural Talimogene Laherparepvec for Patients With Malignant Pleural Effusion
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Cancer; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
- 16 May 2019 Status changed from not yet recruiting to recruiting.
- 07 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 Mar 2019.
- 14 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.